Efficacy of brolucizumab for diabetic macular edema and identification of treatment-resistant factors

Efficacy of brolucizumab for diabetic macular edema and identification of treatment-resistant factors - Efficacy of brolucizumab for diabetic macular edema and identification of treatment-resistant factors

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059703

Enrollment

Registered

2025-11-08

Start date

2025-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema

Interventions

Brolucizumab intravitreal injection Aqueous humor collection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with DME (regardless of severity) 2) Patients aged 20 years or older (regardless of gender) 3) Patients with untreated DME 4) Outpatients 5) Patients who have provided written informed consent to participate in this study 6) Patients with baseline corrected visual acuity between 0.8 and 0.05 7) Patients who selected the brolucizumab treat and extend regimen

Exclusion criteria

Exclusion criteria: 1) Active intraocular or periorbital infection; history of idiopathic/autoimmune uveitis 2) Cases suspected of having a history of retinal vasculitis/occlusive retinal vasculitis 3) Neovascular glaucoma 4) Cerebral infarction/myocardial infarction within the past 6 months 5) Undergoing dialysis 6) Severe hypersensitivity to fluorescein or iodine 7) Patients deemed unsuitable for the study at the physician's discretion

Design outcomes

Primary

Measure	Time frame
Change in best corrected visual acuity (BCVA)	—

Countries

Japan

Contacts

Public ContactKazuma Saito

Gunma University Ophthalmology

kazuma3110@gunma-u.ac.jp027-220-8338

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026